TransCode Therapeutics (NASDAQ:RNAZ) Releases Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) posted its quarterly earnings results on Friday. The company reported ($21.28) EPS for the quarter, FiscalAI reports.

TransCode Therapeutics Stock Performance

Shares of RNAZ stock traded down $0.19 during midday trading on Friday, reaching $6.60. 6,370 shares of the company were exchanged, compared to its average volume of 6,821. TransCode Therapeutics has a 12 month low of $6.08 and a 12 month high of $20.99. The company has a market cap of $6.05 million, a P/E ratio of -0.07 and a beta of 1.39. The company’s 50 day moving average price is $8.58 and its two-hundred day moving average price is $8.96.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.